Recent phase III clinical studies also showed that VEGFR TKIs significantly increase PFS when used as a maintenance therapy [27, 29], suggesting that an antiangiogenic strategy is a valid and important treatment option for ovarian cancer. This evidence concerns the gene KDR and ovarian carcinoma.